Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report released on Friday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $2.00 target price on shares of Aptose Biosciences in a research report on Friday, January 10th.

Aptose Biosciences Trading Down 1.7 %

APTO stock opened at $0.21 on Friday. The firm has a 50 day simple moving average of $0.22 and a 200-day simple moving average of $0.37. The company has a market capitalization of $12.36 million, a P/E ratio of -0.07 and a beta of 0.87. Aptose Biosciences has a twelve month low of $0.13 and a twelve month high of $2.20.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp grew its position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 401,750 shares of the biotechnology company’s stock after acquiring an additional 167,282 shares during the quarter. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 as of its most recent filing with the SEC. 26.62% of the stock is currently owned by hedge funds and other institutional investors.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.